Conflict of Interest Statement
Muscular Dystrophy, Myasthenia Gravis
MUSCULAR DYSTROPHY, MYASTHENIA GRAVIS
Richard J. Nowak reports research support from the National Institutes of Health, Genentech, Inc., Alexion Pharmaceuticals, Inc., argenx, Annexon Biosciences, Inc., Ra Pharmaceuticals, Inc. (now UCB S.A.), the Myasthenia Gravis Foundation of America, Inc., Momenta Pharmaceuticals, Inc., Immunovant, Inc., Grifols, S.A., and Viela Bio, Inc. (Horizon Therapeutics plc). Dr. Nowak has also served as a consultant and advisor for Alexion Pharmaceuticals, Inc., argenx, Cabaletta Bio, Inc., CSL Behring, Grifols, S.A., Ra Pharmaceuticals, Inc. (now UCB S.A.), Immunovant, Inc., Momenta Pharmaceuticals, Inc., and Viela Bio, Inc. (Horizon Therapeutics plc). Ari Breiner reports grant support from the Muscular Dystrophy Association and Muscular Dystrophy Canada. Dr. Breiner has served as an advisor for Alnylam, and has received speaker fees from Mitsubishi‐Tanabe. Vera Bril has served as a consultant for Grifols, CSL, UCB, argenx, Takeda, Alnylam Octapharma, Pfizer, Powell Mansfield Inc, Akcea, Ionis Immunovant, Sanofi, Momenta (J&J), Roche, Janssen, AZ‐Alexion, and NovoNordisk. Dr. Bril also reports research support from AZ‐Alexion, Grifols, CSL, UCB, argenx, Takeda, Octapharma, Akcea, Momenta (J&J), Immunovant, and Ionis. Jeffrey A. Allen has served as a consultant for argenx, Alexion, Annexon, CSL Behring, Takeda, ImmunoPharma, Grifols, Pfizer, Johnson and Johnson. Shaida Khan has served as a consultant for UCB Pharmaceuticals. Dr. Khan has served on advisory boards for Alexion, UCB Pharmaceuticals, argenx, and Immunovant, Inc. Dr. Khan has received research support from the Fichtenbaum Charitable Trust. Todd Levine has served as a consultant for Immunovant, Inc. Daniel H. Jacobs has no disclosures to report for the last 3 years. Gregory Sahagian received consulting and/or research fees from Biogen, UCB, argenx, Alexion and Immunovant. Zaeem A. Siddiqi has served as a consultant for Pfizer, Grifols, CSL Behring, UCB, Takeda, Alnylam. Octapharma, and AZ‐Alexion and has received research support from Pfizer AZ‐Alexion, Grifols, CSL Behring, UCB, Takeda, and Octapharma. Jing Xu: Employee of Immunovant, Inc (New York, NY). William L. Macias: Employee of Immunovant, Inc (New York, NY). Michael Benatar reports grants from the National Institutes of Health and the Muscular Dystrophy Association; as well as consulting fees for Alector, Alexion, Annexon, Arrowhead, Biogen, Cartesian, Denali, Eli Lilly, Horizon, Immunovant, Janssen, Novartis, Orphazyme, Roche, Sanofi, Takeda, UCB and UniQure. The University of Miami has licensed intellectual property to Biogen to support design of the ATLAS study.